Core Viewpoint - The new controlling shareholder Xu Xiren has completed a management reshuffle at Peking University Pharmaceutical, but the company faces significant operational challenges and potential revenue loss due to the termination of key contracts with its largest client, Peking University International Hospital [2][5][6]. Group 1: Management Changes - After taking control, Xu Xiren appointed himself as CEO and made significant changes to the management team, including the resignation of long-standing executives [3][12]. - The previous management team, which had successfully turned around the company's performance, has largely departed, raising concerns about continuity and stability [12][14]. Group 2: Operational Challenges - Peking University Pharmaceutical is experiencing disruptions due to historical issues related to employee benefits, leading to protests from retired staff that have affected administrative operations [5]. - The company has relied heavily on its relationship with Peking University International Hospital, which accounted for approximately 78% of its drug distribution revenue in 2024 [15][16]. Group 3: Financial Implications - The termination of the contract with Peking University International Hospital, which was valued at 12 billion yuan over three years, poses a risk of losing approximately 910 million yuan in annual sales and 36.66 million yuan in net profit starting in 2025 [19][22]. - Despite the termination, the company had previously indicated a potential future collaboration worth 40.5 million yuan, but this has been contradicted by recent statements confirming the end of all cooperation [20][22].

Group 1 - The new actual controller of Beijing University Pharmaceutical, Xu Xiren, has completed a management reshuffle within eight months of taking control [1][2][6] - The company has faced operational disruptions due to historical issues related to retirement benefits and housing, affecting its administrative order [3][7] - The termination of cooperation with Peking University International Hospital, which was the company's largest client, poses a significant challenge to revenue stability [3][9] Group 2 - Xu Xiren acquired control of Beijing University Pharmaceutical at a symbolic price of 1 yuan, gaining control over a company valued at nearly 4 billion yuan [5][6] - The management changes initiated by Xu Xiren have led to the departure of key executives, including the former president who had significantly improved the company's performance [6][7] - The company’s revenue from pharmaceutical distribution was 1.437 billion yuan in 2024, with a substantial portion linked to Peking University International Hospital [7][8] Group 3 - A long-term service contract worth 1.2 billion yuan per year with Peking University International Hospital is set to expire in April 2025, raising concerns about future revenue [8][9] - If the company fails to win the upcoming tender for the hospital's procurement needs, it could face a revenue drop of approximately 910 million yuan and a net profit loss of about 36.66 million yuan starting in 2025 [9]

Group 1: Management Changes - The board of North China Pharmaceutical (000788) appointed Xu Xiren as the new president and Yu Mengchuan as the executive vice president, effective from the date of the board meeting approval until the end of the current board term [1] - Xu Xiren, born in April 1979, holds a master's degree and is the chairman and general manager of New Advantage Industry Group Co., Ltd. He indirectly holds 132 million shares of the company, accounting for 22.22% of the total share capital, making him the actual controller of the company [2] - Yu Mengchuan, born in September 1972, has a graduate degree and has held various managerial positions within North China Pharmaceutical and its subsidiaries [2] Group 2: Historical Issues - On July 1, North China Pharmaceutical reported disruptions at its office caused by nearly a hundred retired employees, which severely affected administrative operations [3] - The company stated that this incident did not impact its production and operational order significantly, and it is working to minimize the effects [3] - North China Pharmaceutical has called for the restoration of the rule of law and supports resolving issues through legal means [3] Group 3: Financial Performance - North China Pharmaceutical's revenue for 2024 was 2.06 billion yuan, a decrease of 6.1% year-on-year, while net profit was 138 million yuan, a significant increase of 211.1% [4] - The first quarter of 2025 saw revenue of 502 million yuan and a net profit attributable to shareholders of 45.64 million yuan [4] - The company reported a total of 772 employees, with 744 receiving salaries, and indicated that there were no retired employees for whom the parent company and major subsidiaries needed to bear costs [4] Group 4: Recent Developments - Since the change of actual controller in December 2024, North China Pharmaceutical has experienced frequent personnel changes [5] - The resignation of the previous president, Yuan Pingdong, was noted as significant, given his contributions to the company's profitability [6] - The new management faces the challenge of addressing historical issues stemming from past commitments and responsibilities following the company's restructuring [6]

证券代码：000788 证券简称：北大医药 公告编号：2025-050 北大医药股份有限公司 关于补选公司第十一届董事会非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为完善公司法人治理结构，确保公司董事会规范运作，根据《公司法》《深 圳证券交易所上市公司自律监管指引第 1 号-主板上市公司规范运作》《公司章 程》等有关规定，经公司主要股东提名，公司第十一届董事会提名委员会审核， 公司于 2025 年 7 月 4 日召开第十一届董事会第十一次会议，审议通过了《关于 补选公司第十一届董事会非独立董事的议案》，董事会同意提名陈岳忠先生为公 司第十一届董事会非独立董事候选人，并提请公司股东大会审议，任期自股东大 会审议通过之日起至第十一届董事会任期届满之日止。 本次补选非独立董事事项已经董事会提名委员会审议通过，尚需提交公司股 东大会审议。本次补选非独立董事工作完成后，董事会中兼任公司高级管理人员 以及由职工代表担任的董事人数总计未超过公司董事总数的二分之一。 非独立董事候选人简历详见附件。 该事项尚需提交公司股东大会审议。 特此公告。 二〇二五年 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-049 北大医药股份有限公司 关于聘任公司总裁及常务副总裁的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日召开第十一 届董事会第十一次会议，审议通过了《关于聘任公司总裁及常务副总裁的议案》。 董事会决定聘任徐晰人先生为公司总裁、余孟川先生为公司常务副总裁，任期自 第十一届董事会第十一次会议审议通过之日起至第十一届董事会届满之日止。 本次聘任的公司总裁及常务副总裁均具备与其行使职权相适应的任职条件， 不存在《公司法》、《深圳证券交易所股票上市规则》及《公司章程》等规定的不 得担任公司高级管理人员的情形，不属于失信被执行人，未受过中国证监会及其 他有关部门的行政处罚和证券交易所纪律处分，不存在因涉嫌犯罪被司法机关立 案侦查或涉嫌违法违规被中国证监会立案稽查的情形,任职资格和聘任程序符合 相关法律法规、规范性文件要求及《公司章程》的规定。 高级管理人员简历附后。 特此公告。 北大医药股份有限公司 董 事 会 二〇二五年七月五 ...

北大医药股份有限公司 证券代码：000788 证券简称：北大医药 公告编号：2025-047 | 制造业，信息传输、软件和信息技术服务业，批 | 发和零售业，水利、环境和公共设施管理业，电 | | | --- | --- | --- | | 力、热力、燃气及水生产和供应业，科学研究和 | 涉及主要行业 | 技术服务业，农、林、牧、渔业，文化、体育和 | | 娱乐业，建筑业，房地产业，租赁和商务服务业， | 采矿业，金融业，交通运输、仓储和邮政业，综 | | | 合，卫生和社会工作等 | | | | 本公司同行业上市公司审计客户家数 | 578 | | 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日召开第十 一届董事会第十一次会议审议通过了《关于续聘会计师事务所的议案》，同意续 聘天健会计师事务所（特殊普通合伙）（以下简称"天健会所"）作为公司 2025 年度审计机构。《关于续聘会计师事务所的议案》尚需提交公司股东大会审议。 现将相关事项公告如下： 一、拟续聘 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-051 北大医药股份有限公司 关于设立公益基金会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、设立公益基金会的基本情况 1、名称：重庆建渝基金会（暂定名）； 2、类型：非公募基金会； 3、原始基金数额：500 万元（人民币），来源于公司捐赠； 4、主管部门：重庆市民政局； 5、业务范围：包括但不限于医疗救助、社会救济、医药医疗科研支持、医 药医疗行业赋能、健康倡导等。以上事项具体以行政主管机关的登记核准情况为 准。 二、捐赠事项概况 北大医药股份有限公司（以下简称"公司"）秉持可持续发展理念，积极支 持公益慈善事业。公司为响应国家"健康中国 2030"战略，弥补医疗健康领域公 益资源缺口，整合医疗健康行业（药企、医疗机构、科研单位等）资源，推动普 惠医疗、贫困救助、医药医疗科研创新等，同时也为加强公司公益事业的规划和 管理，更好履行作为公众公司的社会责任，持续提升公司品牌的影响力，公司拟 出资人民币 500 万元发起设立公益基金会。公司于 2025 年 7 月 4 日召开第十一 届董 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-048 北大医药股份有限公司 关于同意公司全资子公司新优势（重庆）健康产业发展 有限公司使用自有资金开展证券投资业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 3.投资方式 1、投资种类：全资子公司新优势（重庆）健康产业发展有限公司（以下简 称"新优势（重庆）"）运用自有资金，使用独立的自营账户，开展场内股票、 债券投资，不包含衍生品交易。 2、投资金额：用于证券投资的资金为新优势（重庆）自有资金，以其注册 资本人民币 3,000 万元为基础，投资取得的收益可进行再投资，再投资的金额不 包含在初始投资的人民币 3,000 万元以内。新优势（重庆）用于证券投资的总额 度不超过北大医药股份有限公司（以下简称"公司"）最近一期经审计净资产的 10%，在该额度范围内，用于投资的资本金循环使用。 3、特别风险提示：证券投资是一种风险投资。公司全资子公司新优势（重 庆）进行证券投资将受到宏观经济、行业周期、财政及货币政策等多种因素影响， 而且也存在相关工作人员的操作风险，因此新优势 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-046 1、审议通过《关于续聘会计师事务所的议案》 经公司董事会审计委员会审核通过，为保持审计工作的连续性，公司拟续聘 天健会计师事务所（特殊普通合伙）作为公司 2025 年度审计机构。相关内容参 见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于拟续聘会 计师事务所的公告》。 本议案已经董事会审计委员会审议通过。 表决结果：赞成票 8 票，反对票 0 票，回避票 0 票，弃权票 0 票。 本议案尚需提交公司股东大会审议。 北大医药股份有限公司 第十一届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北大医药股份有限公司（以下简称"公司"）第十一届董事会第十一次会议 于 2025 年 7 月 4 日上午在重庆市北碚区方正大道 22 号公司水土厂区 604 一楼 小会议室以现场结合通讯方式召开。会议通知于 2025 年 6 月 30 日以传真、电子 邮件或送达方式发给各位董事。本次会议应出席董事 8 人，实际出席董事 ...

Core Viewpoint - The company, Peking University Medicine (000788), announced that its wholly-owned subsidiary, New Advantage Health Industry Development Co., Ltd., will utilize its own funds to engage in securities investment activities [1] Summary by Categories Investment Details - The investment will be based on a registered capital of RMB 30 million, with the potential for reinvestment of the profits generated from the investments, excluding the initial investment amount of RMB 30 million [1] - The total investment amount for securities will not exceed 10% of the company's most recent audited net assets, allowing for the capital to be recycled within this limit [1] - The investment methods will include on-market stock and bond investments, explicitly excluding derivative trading [1] - The investment period is valid for 12 months from the date of approval by the board of directors [1]